Advertisement

Psychopharmacology

, Volume 74, Issue 3, pp 208–212 | Cite as

Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabis

  • Jan-Erik Lindgren
  • Agneta Ohlsson
  • Stig Agurell
  • Leo Hollister
  • Hamp Gillespie
Original Investigations

Abstract

Δ9-Tetrahydrocannabinol (Δ9-THC) was administered in a crossover design by smoking and IV injection to groups of heavy and light users of marihuana. Plasma concentrations of Δ9-THC were similar for the groups after IV injection of 5.0 mg Δ9-THC, but the AUC0–240 min showed a trend towards lower values for the heavy user group. To achieve a maximum desired “high”, both groups smoked similar amounts (about 13 mg) of Δ9-THC. Heavy users tended to have higher plasma levels than light users. The systemic availability of smoked Δ9-THC was significantly higher for the heavy users (heavy users 23±16% vs 10±7% for light users). These results also indicate that heavy cannabis users smoke more efficiently than casual smokers.

Both light and heavy users showed more clinical effect following IV administration than after smoking. The response of the heavy users, both with respect to effect on heart and “high”, was quite comparable to that of light users.

The present study does not suggest that tolerance readily develops in heavy users.

Key words

Δ9-Tetrahydrocannabinol Pharmacokinetics Plasma levels Marihuana Cannabis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Refrences

  1. Benowitz NL, Jones RT (1977) Effects of Δ9-tetrahydrocannabinol on drug distribution and metabolism. Clin Pharmacol Ther 22:259–268Google Scholar
  2. Hollister LE (1973) Cannabidiol and cannabinol in man. Experientia 29:825–826Google Scholar
  3. Hollister LE (1979) Cannabis and the development of tolerance. In: Nahas G, Paton WDM (eds) Marihuana: Biological effects. Pergamon Press, London, pp 585–589Google Scholar
  4. Hollister LE, Kanter SL, Moore F, Green DE (1972) Marihuana metabolites in urine of man. Clin Pharmacol Ther 13:849–855Google Scholar
  5. Lemberger L, Rubin A (1976) Physiologic disposition of drugs of abuse. Spectrum Publications, New York, pp 269–310Google Scholar
  6. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: Studies on the disposition and metabolism of Δ9-tetrahydrocannabinol in man. Science 170:1320–1322Google Scholar
  7. Ohlsson A, Lindgren JE, Wahlén A, Agurell S, Hollister LE, Gillespie H (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416Google Scholar
  8. Perez-Reyes M, Timmons MC, Wall ME (1974) Long-term use of marihuana and the development of tolerance or sensitivity to Δ9-tetrahydrocannabinol. Arch Gen Psychiatry 31:89–91Google Scholar
  9. Willette RE, ed. (1976) Cannabinoid assays in humans. NIDA Research Monograph 7. National Institute on Drug Abuse, RockvilleGoogle Scholar

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Jan-Erik Lindgren
    • 1
  • Agneta Ohlsson
    • 2
  • Stig Agurell
    • 1
    • 2
  • Leo Hollister
    • 3
  • Hamp Gillespie
    • 3
  1. 1.Astra läkemedel ABSödertäljeSweden
  2. 2.Department of PharmacologyKarolinska InstituteStockholmSweden
  3. 3.Veterans Administration HospitalPalo AltoUSA

Personalised recommendations